Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1802999 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.
Cancer
September 2024
Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Cancer treatment has become increasingly expensive, partially due to the use of specialty drugs. The costs of these drugs are often passed down to patients, who may face the consequences of paying for more than they can afford, leading to financial toxicity. The 340B drug pricing program is a health care policy that may provide an opportunity to mitigate the financial consequences of cancer care.
View Article and Find Full Text PDFCommunity Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes.
Innov Pharm
November 2023
PrimaryOne Health.
: The 340B Drug Pricing Program provides discounted drug prices to safety-net entities which help stretch scarce resources to expand comprehensive services and treat more vulnerable patients. The program has received criticism questioning whether the original intentions are being accomplished. : This qualitative study aimed to understand lived experiences of patients accessing high-cost injectable diabetes medication(s) through a 340B Prescription Cash Discount Program (PCDP) provided at a community health center.
View Article and Find Full Text PDFArticle Synopsis
- The 340B Drug Pricing Program significantly impacts the US healthcare system, accounting for about 1% of total spending, and decisions made about it affect safety net services nationwide.
- A scoping review of existing literature reveals that nonprofit hospitals involved in the program may prioritize financial margins, though evidence of increased community engagement is weak and varies by hospital type.
- The review encompasses 44 peer-reviewed studies, highlighting common research questions and categorizing the literature based on the motivation behind 340B use and the types of healthcare entities involved.
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs.
JAMA Health Forum
June 2023
Division of Health Care Delivery Research, Mayo Clinic, Rochester, Minnesota.
Importance: Previous studies have found that hospitals participating in the 340B Drug Pricing Program have higher Medicare Part B spending and expansion into affluent neighborhoods. Less is known about the association of 340B participation with spending by commercial insurance, where reimbursements are higher than Medicare.
Objective: To use the Affordable Care Act expansion of eligibility for the 340B Drug Pricing Program to study the association between participation and spending on outpatient-administered oncological drugs for commercially insured patients.
The unintended consequences of the 340B safety-net drug discount program.
Health Serv Res
April 2020
Department of Medicine, Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, California.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!